Endospan’s Nexus Duo Aortic Arch Stent Graft System Evaluated in Initial Experience in Europe

June 19, 2023—Endospan announced the presentation of findings from the initial experience with its custom-made Nexus Duo aortic arch stent graft system, which is custom-built based on each patient’s anatomy and physician’s preferences to mitigate stroke risks and provide high procedural success, noted the company.

Professor Theodosios Bisdas, MD, presented the multicenter European experience of the first 10 patients treated with Nexus Duo at LINC, the Leipzig Interventional Course, held June 6-9 in Leipzig, Germany. Prof. Bisdas is with the Athens Medical Centre in Greece.

The Nexus Duo is built on the clinically established technology of the Nexus aortic arch stent graft system. In January 2023, Augusto D’Onofrio, MD, et al, published “Three-year Follow Up of Aortic Arch Endovascular Stent-Grafting with the Nexus Device: Results from a Prospective Multicentre Study” in European Journal of Cardio-Thoracic Surgery. The single-branch Nexus endovascular branch system received CE Mark approval in 2019.

According to the company, the Nexus and Nexus Duo systems provide a minimally invasive endovascular alternative for aortic arch repair, reducing procedure and hospitalization times. In the United States, the Nexus aortic arch stent graft system is an investigational device limited by United States law to investigational use, advised the company.

In Endospan’s press release, Prof. Bisdas commented, “Ten patients were successfully treated with clinical outcomes in line with Nexus single branch. Aortic arch pathologies often require a tailored solution for each complex anatomy. The Nexus Duo provides many anatomical variations while optimizing the treatment.”

Professor Mario Lachat, MD, from Hirslanden Klinik in Zurich, Switzerland, added, “The Nexus Duo’s second branch channel allows transfemoral introduction of all stent grafts necessary for complete endovascular arch repair, with minimal manipulation of supra-aortic vessels—the latter mitigating significantly the stroke risk.”

Endospan CEO Kevin Mayberry stated in the press release, “Our experience with the Nexus in Europe and the United States TRIOMPHE investigational device exemption study both validate the need for an endovascular aortic arch solution.”

Mayberry continued, “The Nexus Duo expands the Nexus platform. The current single-branch Nexus is off the shelf and available for patients requiring urgent life-saving treatment. The Nexus Duo gives physicians more options for less urgent cases to treat the most complex aortic arch anatomies.”